Shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) have been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the stock. One investment analyst has rated the stock with a sell recommendation and nine have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $28.33.

ADMS has been the subject of a number of research analyst reports. Mizuho reiterated a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, September 23rd. Credit Suisse Group AG reiterated a “buy” rating and issued a $21.00 target price on shares of Adamas Pharmaceuticals in a research note on Monday, July 25th. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Noble Financial reiterated a “buy” rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a research note on Friday, July 22nd. Finally, JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Sunday, November 6th.

In other news, major shareholder Ix Lp Mdv purchased 62,977 shares of the firm’s stock in a transaction dated Friday, September 16th. The stock was bought at an average price of $16.48 per share, with a total value of $1,037,860.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William W. Ericson purchased 60,846 shares of the firm’s stock in a transaction dated Wednesday, September 7th. The stock was purchased at an average cost of $15.68 per share, with a total value of $954,065.28. The disclosure for this purchase can be found here. Company insiders own 31.79% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Great Point Partners LLC purchased a new position in shares of Adamas Pharmaceuticals during the third quarter valued at about $42,688,000. Brenner West Capital Advisors LLC raised its position in shares of Adamas Pharmaceuticals by 15.0% in the third quarter. Brenner West Capital Advisors LLC now owns 1,169,275 shares of the specialty pharmaceutical company’s stock valued at $19,188,000 after buying an additional 152,275 shares during the period. BlackRock Fund Advisors raised its position in shares of Adamas Pharmaceuticals by 7.5% in the third quarter. BlackRock Fund Advisors now owns 757,473 shares of the specialty pharmaceutical company’s stock valued at $12,430,000 after buying an additional 52,736 shares during the period. Vanguard Group Inc. raised its position in shares of Adamas Pharmaceuticals by 24.3% in the second quarter. Vanguard Group Inc. now owns 618,782 shares of the specialty pharmaceutical company’s stock valued at $9,369,000 after buying an additional 120,912 shares during the period. Finally, Emerald Mutual Fund Advisers Trust raised its position in shares of Adamas Pharmaceuticals by 2.1% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 571,789 shares of the specialty pharmaceutical company’s stock valued at $9,383,000 after buying an additional 11,910 shares during the period. 72.41% of the stock is owned by institutional investors.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 15.97 on Monday. Adamas Pharmaceuticals has a 12 month low of $12.02 and a 12 month high of $31.84. The firm’s market cap is $351.05 million. The stock’s 50 day moving average price is $15.07 and its 200-day moving average price is $15.41.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.17. Adamas Pharmaceuticals had a negative net margin of 5,267.99% and a negative return on equity of 38.31%. The company earned $0.14 million during the quarter, compared to analysts’ expectations of $0.26 million. During the same quarter in the previous year, the company posted ($0.81) earnings per share. Adamas Pharmaceuticals’s quarterly revenue was down 81.8% compared to the same quarter last year. Equities research analysts anticipate that Adamas Pharmaceuticals will post ($2.91) earnings per share for the current fiscal year.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

5 Day Chart for NASDAQ:ADMS

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.